HeartBeam Business Summary

HeartBeam, Inc. (BEAT) operates as a medical technology firm specializing in remote cardiac diagnostic solutions through its proprietary 3D vector electrocardiography (VECG) platform. The company generates revenue via a B2B2C model, primarily through the sale of its flagship HeartBeam AIMIGo™ hardware—a credit-card-sized, cable-free 12-lead ECG equivalent—and recurring service fees for its cloud-based monitoring software and on-demand cardiologist review services. As of early 2026, the company is transitioning into a commercial-stage entity following key FDA 510(k) clearances for its arrhythmia assessment software, targeting concierge cardiology and preventive care practices. HeartBeam competes directly with AliveCor, iRhythm Technologies, GE HealthCare, and SHL Telemedicine, positioning itself as a high-resolution alternative that bridges the gap between consumer-grade single-lead wearables and clinical-grade hospital ECG systems. The leadership team is anchored by Founder and President Branislav Vajdic, PhD, a veteran of the semiconductor and medtech industries who previously founded NewCardio and held senior management roles at Intel. Chief Executive Officer Robert P. Eno leads the commercialization strategy, bringing over 30 years of experience from leadership roles at HeartFlow and Preview Medical. The executive suite includes Chief Technology Officer Ken Persen, formerly of LIVMOR, and Chief Commercial Officer Bryan Humbarger, who joined in early 2026 to scale U.S. market entry. The company is supported by a high-pedigree board of directors chaired by Rich Ferrari, co-founder of De Novo Ventures, and includes notable investor Mark Strome, founder of the Strome Group, alongside former executives from iRhythm and Boston Scientific.